Remember that you can feel free to subscribe to our own penny stock alerts at www.pennystockdream.com. Our Platinum Members saw our alerts on the very best penny stocks gain 184,374% in the past 6 weeks! Subscribe to become a Platinum Member at www.pennystockdream.com/platinum.

Fellow Investor,

Tonight's alert fights the battle against many forms of cancer which has been a long and arduous one but every now and then a company comes along that defies what many so-called experts say can’t work.

One such company is our latest alert and its growth potential just got amped up courtesy of some stunning news about one of its cancer products.

For years many thought that inoperable pancreatic cancer would be a death sentence for sufferers but now courtesy of this explosive company people suffering can see a light at the end of the tunnel.

And their light is your golden opportunity to benefit from a massively undervalued play filled with solid upside potential.

Ready for more?

Let's jump right to it... Nuvilex Inc. (OTCQB: NVLX)

NVLX has been a provider of all-natural products for many years.

NVLX has expanded and is now offering a broader base of natural products, which now include products, developed through medical marijuana studies.

NVLX is also becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine.

NVLX’s offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development.

NVLX’s mission has been and continues to be to develop, manufacture, and market products that are “Good for You, Good for the Environment.”

NVLX acquired a new subsidiary, Bio Blue Bird AG ("BBB"), which included its worldwideexclusive licenses, for the live-cell encapsulation-based pancreatic cancer treatment and the use of the live-cell encapsulation technology for the development of treatments for many types of cancer.

With the exclusive licenses now owned by a NVLX, management is having the cells assessed and prepared for the planned pancreatic cancer trial, engaging Austrianova Singapore for GMP encapsulation, preparing to have the protocol designed and complete all necessary regulatory steps required to conduct a new clinical trial based upon the use of the live-cell encapsulation-based cancer treatment.

All of the production and manufacturing of the encapsulated cells required for future studies will be carried out by Austrianova Singapore. In connection with the acquisition of BBB, NVLXacquired a 14.5% ownership stake in SG Austria.

Another key goal for NVLX is their intentions to acquire the worldwide exclusive rights to the use of the live-cell encapsulation technology for the development of treatments for diabetes from SG Austria.

NVLX anticipates closing the acquisition on or about October 31, 2013.(Note: funds for this acquisition have already been committed, the final paperwork is executed, and was reported in the recent 8-K submitted to the SEC July 17, 2013.) 

NVLX management believes that a significant opportunity exists in utilizing the live-cell encapsulation treatment for diabetic patients as early tests have demonstrated the potential elimination of the need for insulin therapy. NVLX is planning for future in-depth studies to begin in early 2014.

 

 

As part of its long-term financial objectives, NVLX has strengthened its balance sheet to a level not achieved in over 2 years. As one big example of this, the Company settled a $2.2M debt owed to Cornerstone Bank, thus eliminating the largest single liability from its balance sheet. The removal of this line item will be reflected in future filings. Moreover, management expects that the balance sheet will continue to improve in the coming quarters. (Source: Nuvilex Provides Shareholder Update)

 

Biotech Undergoes Resurgence – IPOs Increasing at Rapid Pace

Biotechnology companies are raising money at the fastest rate since the dotcom boom.

So far this year, 22 companies have raised $1.7 Billion from initial public offerings in the US and several more are scheduled to list in the coming months, according to Dealogic.

That surpasses the total amount raised in biotech IPOs in 2011 and 2012 combined and puts the sector on course for its most active year of issuance since 2000.

Shares in these companies have averaged first-day “pops” of 18 per cent and are typically trading 43 per cent higher than their debut price, the data provider said.

The surge in IPO activity comes amid fresh optimism in the broader pharmaceutical sector, as demonstrated by renewed appetite for big deals including Perrigo’s $8.6 Billion bid for Ireland-based Elan this week and Amgen’s $10 Billion unsolicited takeover proposal for Onyx Pharmaceuticals last month.

Goldman Sachs is advising Alexion Pharmaceuticals of the US, which has a market capitalisation of $22.8 Billion and according to some reports, is a possible bid target for Roche

Agios Pharmaceuticals, which is developing drugs to treat cancer and rare genetic disorders, raised $122 Million from an IPO last week and its shares jumped 73.8 per cent on the first day of trading. It attracted huge investor demand even though it has not started clinical trials on any of its drugs, reflecting the growing trend for investors to snap up shares in companies at a much earlier stage in the development process.

Historical data suggest that a company in phase-one clinical trials has only a 10 per cent chance of successfully bringing a drug to market, according to industry analysts.

Richard Truesdell, co-head of Davis Polk & Wardwell’s global capital market practice, said investments in biotech IPOs tended to be all-or-nothing bets with a high chance of failure, and that companies were rushing to market to take advantage of a renewed appetite for risk.

He said: “We are clearly seeing an increasing ‘risk-on’ mentality among investors.”

That appetite is broadening the range of investors considering deals, which were once mainly looked at by niche funds with specialists in the sector.

Rachel McMinn, analyst at Bank of America Merrill Lynch, said: “The danger of all of these companies coming public is that a lot of them are going to fail because drug development isn’t that easy. It’s all great, until it’s not.”

Attempts by the US Food and Drug Administration to be more responsive to drug companies, including the introduction of programmes designed to hasten the approval process, have improved sentiment. The regulator approved 39 drugs last year, the highest number in more than a decade and 14 in 2013.

The jump in demand for fledgling drug developers searching for cures to the world’s most serious illnesses is reflected in the Nasdaq Biotechnology index, which has risen 43 per cent this year, outpacing the 18.6 per cent gains on the S&P 500 and all major industry groups on the US benchmark.

With such renewed optimism towards the biotech industry, NVLX couldn’t have picked a better time to define itself as a wholly biotech-driven operation.

Its growth potential should now take on a more defined form and investors should have even more confidence in its gain potential.

NVLX has "long term growth" written all over it and investors should start to take notice right away!

Make sure you place NVLX on your screen tomorrow morning and stay tuned for further updates on this company.